Get the Stockscreener App
1.45
7.64%
-0.12
After Hours:
1.49
0.04
+2.76%
Palisade Bio Inc stock is traded at $1.45, with a volume of 5.72M.
It is down -7.64% in the last 24 hours and down -29.95% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.57
Open:
$1.57
24h Volume:
5.72M
Relative Volume:
1.84
Market Cap:
$252.69M
Revenue:
$250.00K
Net Income/Loss:
$-24.15M
P/E Ratio:
-1.3607
EPS:
-1.0656
Net Cash Flow:
$-12.40M
1W Performance:
-8.81%
1M Performance:
-29.95%
6M Performance:
-27.50%
1Y Performance:
+87.58%
1-Day Range:
$1.45
$1.59
1-Week Range:
$1.45
$1.71
52-Week Range:
$0.7871
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.45 | 252.69M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s - Yahoo Finance
Palisade Bio, Inc. (PALI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palisade backs away but others not ‘scarred’ of FSCD - BioWorld News
Palisade Bio at Stifel forum: pde4 bet advances into phase 2 - Investing.com Canada
Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada - Yahoo Finance
Palisade Bio receives Health Canada clearance for UC trial - Investing.com
Palisade Bio receives Health Canada clearance for UC trial By Investing.com - Investing.com Nigeria
Palisade Bio Announces Health Canada Clearance for Global Phase 2 ASCENTRA-UC Study of PALI-2108 in Ulcerative Colitis - quiverquant.com
Palisade Bio, Inc. Receives Health Canada CTA Clearance For ASCENTRA-UC Global Phase 2 Study Evaluating PALI-2108 - marketscreener.com
HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target - TradingView
FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug - Investing.com Nigeria
Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease - Yahoo Finance
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD - markets.businessinsider.com
FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug By Investing.com - Investing.com South Africa
The FDA cleared Palisade Bio’s Crohn’s trial application. First patient dosing is targeted for early 2027. - Stock Titan
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Palisade Bio, Inc.(NasdaqCM: PALI) added to S&P Global BMI Index - marketscreener.com
Palisade Bio at H.C. Wainwright conference: IBD drug push By Investing.com - Investing.com Australia
Palisade Bio at H.C. Wainwright conference: IBD drug push - Investing.com
Palisade Bio at Morgan Stanley conference: broadens ibd push By Investing.com - Investing.com UK
Here's Why We're Not Too Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn Situation - simplywall.st
Palisade Bio (PALI) Advances 5.26% as Shares Test Key Resistance at $2.31Regression Channel - siam.in
Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Three September healthcare conferences will include Palisade Bio management - Stock Titan
Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan
Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView
FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail
Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade
Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia
Palisade Bio clears FDA for Phase 2 UC trial - scanx.trade
Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times
Palisade Bio Q2 net loss widens on higher R&D costs - TradingView
Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - MarketBeat
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Palisade Bio (PALI) Expected to Post Earnings on Monday - MarketBeat
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):